close
Add to watchlist
Cell Therapeutics Inc (CTIC) Healthcare, Biotechnology & Drugs
Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 1.29 |
| Volume | 590512 |
| Volume Avg | (mio) 2.58 |
| 52 Week High | 3.30 |
| 52 Week Low | 0.95 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.71 |
| EPS change Q/Q | -50% |
| EPS change Q/Q Yr ago | -14.29% |
| EPS change Q/Q next Q est | -40% |
| EPS change Y/Y | -35% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | -0.10 |
| EPS next Y est | -0.26 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |